AIM ImmunoTech Inc (STU:HXB2)
€ 0.356 0.002 (0.56%) Market Cap: 18.26 Mil Enterprise Value: 11.88 Mil PE Ratio: 0 PB Ratio: 4.70 GF Score: 40/100

AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 11:00AM GMT
Release Date Price: €0.54 (-3.57%)
Steve Bersey
H.C. Wainwright & Co. - Analyst

Good day, everyone, and thank you for joining the H.C. Wainwright 25th annual global investment conference. My name's Steve Bersey. I'm an equity research associate at H.C. Wainwright.

So now I'd like to welcome Thomas Equels, President and Chief Executive Officer of AIM ImmunoTech. So I'll turn it over to Thomas.

Thomas Equels
AIM ImmunoTech Inc. - President & CEO

Thank you, Steve, and thank you to H.C. Wainwright for the opportunity to talk about the important programs we have underway at AIM ImmunoTech today. We're a public company, so I ask you to look at our forward-looking statements and also go through our Ks and Qs that are filed to review the risks and disclosure items that you'll find in those documents.

Our drug, Ampligen, which is what our principal drug is today, has a number of very important aspects to it. It has a very wide spectrum of opportunity and impact in different disease areas. We have multiple clinical programs going on right now that are generating data. And so

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot